Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DLQ02
- Development stage
- Phase 1
- Lead developer
- Dermaliq Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DLQ02 is a novel, liquid topical calcineurin inhibitor with anti-inflammatory and immunomodulating properties. It is being developed by Dermaliq Therapeutics for the treatment of immune-mediated skin conditions, primarily plaque psoriasis. Unlike oral calcineurin inhibitors that are associated with significant systemic side effects, DLQ02 aims to provide effective localized therapy with reduced risk profiles by leveraging a proprietary topical delivery platform (hyliQ). The drug is currently in Phase 1b/2a clinical trials for mild to moderate plaque psoriasis and represents an effort to address unmet needs in patients who are not candidates for systemic treatments[1][2][3][4][5][7][8].
02
Targets
CN (Calcineurin)
Beyond the preview
Go deeper on DLQ02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLQ02.